Zinc Finger, FYVE Domain Containing Protein 19 (ZFYVE19)

Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocytes infusion (DLI), demonstrating the potency of donor-derived immunity in eradicating tumor. Three antigens, C6orf130, MDS032, and ZFYVE19, were identified by both patients. Along with additional candidate antigens DAPK3, SERBP1 and OGFOD1, these proteins demonstrated higher transcript and protein expression in B cells and CLL cells compared to normal PBMC.While ZFYVE19, DAPK3 and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens.